1. BRCA2 reversion mutation confers resistance to olaparib in breast cancer
- Author
-
Shinya Yamamoto, Kei Kawashima, Yoshie Fujiwara, Shoko Adachi, Kazutaka Narui, Chiaki Hosaka, Rina Takahashi, Sho Tsuyuki, Makoto Sugimori, Miki Tanoshima, Mahato Sasamoto, Masanori Oshi, Akimitsu Yamada, Chikara Kunisaki, and Itaru Endo
- Subjects
BRCA ,breast neoplasms ,genomics ,olaparib ,Medicine ,Medicine (General) ,R5-920 - Abstract
Key Clinical Message A rare missense mutation was identified as a reversion mutation using cancer genomic profiling and a suspected mechanism underlying resistance to olaparib in breast cancer. Abstract A 34‐year‐old woman with breast cancer and BRCA2: p.Gln3047Ter was treated with olaparib. After tumor progression, cancer genomic profiling testing using liquid biopsy revealed BRCA2 p.Gln3047Ter and p.Gln3047Tyr, with 48.9% and 0.37% allele frequency, respectively. These findings shed light on reversion mutation as a mechanism of resistance to olaparib in breast cancer.
- Published
- 2023
- Full Text
- View/download PDF